We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NBBK:NASDAQNB Bancorp, Inc. Analysis

Data as of 2026-05-19 - not real-time

$19.47

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

NB Bancorp is trading well below its discounted cash‑flow estimate, suggesting a sizable valuation gap. The price‑to‑earnings multiple sits beneath the sector average, reinforcing the cheapness perception. A modest dividend yield combined with a low payout ratio points to sustainable cash returns. Revenue growth remains robust, driven by strong loan and deposit activity in its core Massachusetts market. Operating margins are healthy, and return on equity, while modest, is positive. Technicals show the short‑term moving average marginally above the mid‑term average, while the MACD has turned bearish and volume is on a downtrend, indicating near‑term pressure.
Recent earnings missed consensus estimates, adding short‑term downside pressure. However, a board director’s sizable share purchase after the price dip signals insider confidence. Analyst coverage is limited, but the consensus target aligns with the current price, implying limited upside from analyst revisions. The stock’s beta below one and lower‑than‑market volatility suggest defensive characteristics. With a modest dividend and a strong cash position relative to debt, the company is well‑positioned to weather sector headwinds. Overall, the combination of valuation upside, growth fundamentals, and defensive risk profile makes the stock attractive for patient investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • recent earnings miss
  • bearish MACD and declining volume
  • insider share purchase indicating confidence

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • significant valuation upside to DCF
  • strong revenue growth and margins
  • sustainable dividend with low payout

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • defensive beta and lower volatility
  • robust cash position versus debt
  • regional market focus with growth potential

Key Metrics & Analysis

Financial Health

Revenue Growth36.30%
Profit Margin23.31%
P/E Ratio14.2
ROE6.65%
ROA0.84%
P/B Ratio1.0
Op. Cash Flow$78.2M
Industry P/E16.7

Technical Analysis

TrendNeutral
RSI38.3
Support$18.51
Resistance$22.48
MA 20$20.00
MA 50$20.82
MA 200$19.78
MACDBearish
VolumeDecreasing
Fear & Greed Index89.05

Valuation

Fair Value$48.47
Target Price$23.00
Upside/Downside18.13%
GradeUndervalued
TypeGrowth
Dividend Yield1.44%

Risk Assessment

Beta0.73
Volatility39.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.